No Effect of Dose Adjustment to the CYP2D6 Genotype in Patients With Severe Mental Illness

Frontiers in Psychiatry
Anne B KoopmansPeter N van Harten

Abstract

Background: The CYP2D6 enzyme is involved in the metabolism of numerous psychopharmacological drugs. Guidelines recommend how to adjust the dose of medication based on the CYP2D6 genotype. Aims: To evaluate the effect of dose adjustment to the CYP2D6 genotype and phenotype, in patients with severe mental illness (SMI) already receiving psychopharmacological treatment. Methods: A total of 269 psychiatric patients (on the island Curaçao) receiving antipsychotic treatment were genotyped for CYP2D6. Of these, 45 patients were included for dose adjustment according to the clinical guideline of the Royal Dutch Association for the Advancement of Pharmacy, i.e., 17 CYP2D6 poor metabolizers, 26 intermediate metabolizers, and 2 ultrarapid metabolizers. These 45 patients were matched for age, gender, and type of medication with a control group of 41 patients who were CYP2D6 extensive metabolizers (i.e., with a normal CYP2D6 function). At baseline and at 4 months after dose adjustment, subjective experience, psychopathology, extrapyramidal side-effects, quality of life, and global functioning were assessed in these two groups. Results: At baseline, there were no differences between the groups regarding the prescribed dosage of antipsychoti...Continue Reading

References

May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Apr 1, 1993·Acta Psychiatrica Scandinavica·J GerlachD E Casey
Apr 18, 1998·The American Journal of Psychiatry·Peter N van HartenR S Kahn
Jun 17, 2004·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Lieuwe de HaanDon Linszen
Dec 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Sven JannoKristian Wahlbeck
Jan 27, 2005·The Journal of Clinical Psychiatry·Jose de LeonPeter J Wedlund
Mar 5, 2005·Psychiatric Services : a Journal of the American Psychiatric Association·Joyce C WestDarrel A Regier
Apr 30, 2005·Pharmacogenetics and Genomics·Nikolaos A PatsopoulosJohn P A Ioannidis
Jul 27, 2007·Administration and Policy in Mental Health·Nancy H CovellSusan M Essock
Feb 7, 2008·Clinical Pharmacology and Therapeutics·J J SwenVera H M Deneer
Jan 21, 2010·Psychological Medicine·J Moncrieff, J Leo
Nov 16, 2010·Bulletin of the World Health Organization·T Bedirhan UstünWHO/NIH Joint Project
Mar 18, 2011·Clinical Pharmacology and Therapeutics·J J SwenH-J Guchelaar
Dec 30, 2011·Clinical Pharmacology and Therapeutics·K R CrewsClinical Pharmacogenetics Implementation Consortium
Mar 5, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Philip Seeman, Michele Tinazzi
Apr 2, 2013·The Journal of Clinical Psychiatry·Sheldon H PreskornChristine J Guico-Pabia
May 24, 2014·The British Journal of Psychiatry : the Journal of Mental Science·Brendan MulhernJohn Brazier
Jun 11, 2014·British Journal of Clinical Pharmacology·Rashmi R Shah, Robert L Smith
Dec 19, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Rashmi R Shah, Robert L Smith
Feb 1, 2018·Der Nervenarzt·Daniel J Müllerdas DGPPN Referat Neurobiologie und Genetik
Feb 13, 2018·Frontiers in Psychiatry·Alexandre WullschlegerMartin Heinze
Feb 16, 2018·Psychiatric Services : a Journal of the American Psychiatric Association·Matthew L GoldmanHarold Alan Pincus

Related Concepts

Mental Disorders
Pharmaceutical Preparations
Mental Health Associations
Metabolism
Pharmacy (Field)
Psychopathology
Antipsychotic Agents
Cytochrome P-450 CYP2D6
Evaluation
Clinical Practice Guideline

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here